lirilumab + lenalidomide

**lirilumab + lenalidomide** is an investigational combination regimen of two pharmaceuticals: - **Lirilumab** is a fully human monoclonal antibody (IgG4) that blocks the interaction between killer immunoglobulin-like receptors (KIR2DL1, KIR2DL2, KIR2DL3) on natural killer (NK) cells and their HLA-C ligands. By inhibiting KIR/HLA-C interaction, lirilumab lowers the threshold for NK cell activation and potentiates anti-tumor immunity, especially through direct cytotoxicity and cytokine recruitment[1]. - **Lenalidomide** is a small molecule immunomodulator that enhances activation of T-cells and NK cells, inhibits angiogenesis, and exerts anti-neoplastic effects. Commonly used in hematological malignancies, it modifies the tumor microenvironment through multiple immunostimulatory actions[4]. No clinical trials specifically combine lirilumab and lenalidomide directly; published and registered studies have evaluated lirilumab with azacitidine, and lenalidomide either alone or with other agents[1][3][5][4]. Thus, the lirilumab + lenalidomide combination is hypothetical or investigational only.